![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-4781.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-51567.gif)
Active Filter(s):
Details:
Under the acquisition, Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide), a cholinesterase inhibitor, oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.
Lead Product(s): Galantamine Hydrobromide
Therapeutic Area: Neurology Product Name: Reminyl
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2024